In: Scientific Reports, 2020, vol. 10, no. 1, p. 7078
Immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), have resulted in unprecedented improvements in survival for patients with lung cancer. Nonetheless, not all patients benefit equally and many issues remain unresolved, including the mechanisms of action and the possible effector function of immune cells from non-lymphoid lineages. The purpose of this...
|
In: European Journal of Pharmaceutics and Biopharmaceutics, 2019, vol. 139, p. 253–261
Resiquimod (R848), a member of the imidazoquinoline family, is a Toll-like receptor 7/8 agonist with high potency for cancer immunotherapy. However, tolerance induction and adverse effects limit its development as a drug. Encapsulation in a polymer matrix can circumvent these limitations, as shown in our formerly published approach where R848 was loaded into polylactic acid (PLA)-based...
|
In: Seminars in Immunopathology, 2014, vol. 36, no. 1, p. 73-91
|
In: Biomaterials, 2019, vol. 190–191, p. 111–120
Although immunotherapy shows great promise for the long-term control of cancer, many tumors still fail to respond to treatment. To improve the outcome, the delivery of immunostimulants to the lymph nodes draining the tumor, where the antitumor immune response is initiated, is key. Efforts to use nanoparticles as carriers for cancer immunotherapy have generally required targeting agents and...
|
In: World Journal of Pediatrics, 2010, vol. 6, no. 1, p. 5-12
|
In: Springer Seminars in Immunopathology, 2004, vol. 25, no. 3-4, p. 377-390
|
In: Aquatic Sciences, 2005, vol. 67, no. 1, p. 3-14
|
In: European Journal of Nuclear Medicine and Molecular Imaging, 2004, vol. 31, no. 4, p. 547-554
|
In: International Journal of Pharmaceutics, 2018, vol. 535, no. 1, p. 444–451
Small-molecule agonists for the Toll-like receptors (TLR) 7 and 8 are effective for the immunotherapy of skin cancer when used as topical agents. Their systemic use has however been largely unsuccessful due to dose-limiting toxicity. We propose a polymer-based nanodelivery system to target resiquimod, a TLR7 ligand, to the lymph node in order to focus the immunostimulatory activity and to...
|
In: Parasitology, 1989, vol. 98, no. S1, p. S49-S60
|